Compare FGBI & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FGBI | CRBU |
|---|---|---|
| Founded | 1934 | 2011 |
| Country | United States | United States |
| Employees | 346 | N/A |
| Industry | Savings Institutions | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.6M | 166.6M |
| IPO Year | N/A | 2021 |
| Metric | FGBI | CRBU |
|---|---|---|
| Price | $9.29 | $1.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.75 |
| AVG Volume (30 Days) | 67.5K | ★ 2.4M |
| Earning Date | 04-27-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $567.70 | $1.63 |
| Revenue Next Year | N/A | $10.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.31 | $1.38 |
| 52 Week High | $11.02 | $3.53 |
| Indicator | FGBI | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 41.54 | 35.14 |
| Support Level | $8.72 | $1.39 |
| Resistance Level | $9.94 | $1.73 |
| Average True Range (ATR) | 0.36 | 0.11 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 26.14 | 0.94 |
First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana, through several banking facilities. The principal business activity of the company includes attracting deposits and investing it together with funds generated from operations and borrowings insecurities and in lending activities to serve the credit needs of its customer base. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and to a lesser extent, consumer and multifamily loans.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.